THE ARISING · Markets & Strategy
CMS Proposes Medicare Advantage Directory and Part D PBM Rules
Medicare Advantage plans may soon face new provider directory requirements, and pharmacy benefit managers in Part D may face new compensation and transparency rules. The Centers for Medicare & Medicaid Services (CMS) released a proposed rule in the week of October 16, 2026, that covers both. The specific provisions, including section numbers, update schedules, accuracy scores, copay amounts, payment standards, dates and the comment deadline, need confirmation from the CMS proposed rule or Federal Register notice. The page we relied on does not state them.
According to Alston & Bird's Health Care Week in Review, the rule implements sections of the Consolidated Appropriations Act, 2026. The firm describes three areas: provider directory requirements for Medicare Advantage organizations, adjustments to Part D cost-sharing reductions for low-income individuals, and new transparency and compensation requirements for PBMs.
The first change targets provider directories. The source says only that the rule would establish new directory requirements for Medicare Advantage organizations. It gives no detail on how often directories must be updated, whether accuracy would be scored or published, or what protections patients would have when a listing is wrong.
Because the source is thin here, we cannot say when any directory requirement would take effect or how compliance would be measured. Those are the details plans will care about most, and they must be checked against the rule itself.
The second change targets PBMs. The source says the rule would establish new transparency and compensation requirements for PBMs. It does not say what the compensation standard is, who would receive additional reporting, or which agreements would have to be disclosed.
The third change affects cost sharing. The source says the rule would adjust Medicare Part D cost-sharing reductions for low-income individuals. It does not give the amounts, the eligible groups or the start date. Copay changes do not alter anyone's prescriptions; they change who pays what at the pharmacy counter.
The market implications are a matter of interpretation, and the source does not quantify any of them. Stronger directory rules could raise the operational cost of keeping provider data current, and plans that already maintain clean data may be better placed than those that do not. This is our inference, not something the source states.
For PBMs and Part D sponsors, new compensation requirements could change how contracts are written and how much of a drug's price flows to intermediaries. Added transparency would give sponsors and regulators more visibility. How much revenue is affected will depend on the final standard and on current contract terms, neither of which the source describes.
Changes to low-income cost-sharing reductions could shift cost-sharing revenue between plans and enrollees. The size and direction cannot be judged without the rule's figures, so this is the weakest part of the analysis.
This is a proposal, not a final rule. The source gives no comment deadline for it, so readers should check the Federal Register notice. Watch what plans, PBMs and patient groups say in comments, and whether CMS changes its approach before finalizing.